Genmab A/s · OMXCOP:GMAB
Genmab A/s — 44th Annual J.P. Morgan Healthcare Conference 2026
18 slides from Genmab A/s's conference presentation, Jan 13, 2026
Slide 1: Leading antibody science for better futures
Leading antibody science for better futures 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 © Genmab 2026
Slide 2: Forward looking statement
Forward looking This presentation contains forward looking statements. The words “believe”, “expect”, rates of patient recruitment, unforeseen safety issues resulting from the administration of our statement “anticipate”, “intend” and “plan” and similar expressions identify forward looking statement
Slide 3: Delivering Genmab's Next Decade of Sustainable Growth
Delivering Genmab’s Next Decade of Sustainable Growth Nine medicines Two co-owned Three high on the market medicines: impact late- driving revenue TIVDAK® stage assets growth (tisotumab with multiple vedotin) and read-outs in EPKINLY® 2026; positioned /TEPKINLY® for potential 2027 (epcoritamab) laun
Slide 4: Late-stage Pipeline of Attractive Growth Opportunities
Late-stage Pipeline of Attractive Growth Opportunities Peak Annual Sales Potential >$3Bn >$2Bn Multi-$Bn Epkinly® Rina-S® Petosemtamab (Lymphoma) (Gyn-Onc) (HNSCC) FDA Breakthrough Therapy Designations FDA Breakthrough Therapy Designation FDA Breakthrough Therapy Designations • Launch in expanded in
Slide 5: Late-stage Asset Highlights and Differentiation
Late-stage Asset Highlights and Differentiation Epkinly® Rina-S® Petosemtamab (Lymphoma) (Gyn-Onc) (HNSCC) • Only bispecific with dual indication in • Next-generation, FRα-targeted • EGFR x LGR5 bispecific B-cell malignancies* TOPO1 ADC • Compelling efficacy and favorable • Rapid adoption with acces
Slide 6: Seven Recent Data Readouts Supporting 2026 Catalysts
Seven Recent Data Readouts Supporting 2026 Catalysts EPKINLY® Petosemtamab • Ph 3 2L FL (EPCORE® FL-1) • Ph 2 outpatient (EPCORE® • Ph 2 1L r/m HNSCC • Ph 2 mCRC: 1L& 2L combo • Basis for US approval, NHL-6) • Update of data that was w/ FOLFOX/FOLFIRI and RoW reg. submissions • Demonstrated feasibil
Slide 7: 2026: Up to Six Registrational Readouts Enabling 2027 Launches
2026: Up to Six Registrational Readouts Enabling 2027 Launches Rina-S® Petosemtamab • Ph 2 PROC (RAINFOL -01) • Ph 3 1L r/m HNSCC (LiGeR-HN1) and/or Ph 3 2L/3L r/m HNSCC • H2 2026 (LiGeR-HN2) • H2 2026 EPKINLY® • Ph 3 1L DLBCL • Ph 3 2L+ DLBCL mono • Ph 3 2L+ DLBCL combo + len (EPCORE® DLBCL-2) (EPC
Slide 8: Strong Growth Projected for Royalty Medicines Portfolio
Strong Growth Projected for Royalty Medicines Portfolio Net sales (USD)* 2024 2030e DARZALEX1 Kesimpta2 TEPEZZA3 (12% - 20% royalty excl. (10% royalty) (Mid-single digit royalty) Halozyme contribution) • > $6.0B peak sales potential • Approved in U.S., Europe and $11.67B $20.3B** • Share gains acros
Slide 9: Combination Accelerates Revenue Growth and Diversification
Combination Accelerates Revenue Growth and Diversification Increased scale and diversification of revenue Growing to ~4 owned medicines* Illustrative Royalties Rina-S® Royalties Own Products Petosemtamab Own Products *Subject to results/regulatory approvals Darzalex®, Tecvayli®, Rybrevant®, Talvey®,
Slide 10: Track Record of Successful Execution
Track Record of Successful Execution ProfoundBio 2024: Profitability: Merus: Rapid integration A Transformational Delivered as guided Operating discipline and development of Year: Genmab in 2026 Petosemtamab • Closed $1.8B all-cash acquisition of • FY2024 operating profit growth of • Accelerates div
Slide 11: Appendix
¥Genmab Appendix © Genmab 2026 11
Slide 12: Strength of Late-Stage Pipeline: Multibillion-dollar Opportunities
Strength of Late-Stage Pipeline: Multibillion-dollar Opportunities Anticipated Launch in Addressable Patient Opportunity Program Indication Phase Status Indication Population (Peak Sales) 1L DLBCL 3 Fully Recruited 2027 70,000 (EPCORE®DLBCL-2) 2L+ DLBCL 3 Fully Recruited 2027 (EPCORE®DLBCL-1) 21,000
Slide 13: 2026 Priorities
2026 Priorities Program Indication Event Anticipated Timing • Rapid integration of Merus Ph 3 1L DLBCL TLR and reg. Epcoritamab 2026 • Maximize potential of (EPCORE® DLBCL-2) submissions commercialized medicines Ph 3 2L+ DLBCL mono TLR and reg. 2026 EPKINLY® and TIVDAK® (EPCORE® DLBCL-1) submissions
Slide 14: Innovative Pipeline: Ongoing Clinical Trials (Genmab/Partner Sponsored)
Innovative Pipeline: Ongoing Clinical Trials (Genmab/Partner Sponsored) Product Developed Technology Target Trial Name Patient Population Treatment Regimen Phase Primary ClinicalTrials.gov ID Trial Status ~# Primary By Endpoint(s) Patients completion per ct.gov Epcoritamab Co-dev DuoBody® CD3, EPCOR
Slide 15: Innovative Pipeline: Ongoing Clinical Trials (Genmab/Partner Sponsored), Con't
Innovative Pipeline: Ongoing Clinical Trials (Genmab/Partner Sponsored), Con’t Product Developed By Technology Target Trial Name Patient Population Treatment Regimen Phase Primary ClinicalTrials.gov ID Trial Status ~# Patients Primary Endpoint(s) completion per ct.gov Tisotumab vedotin Co-developmen
Slide 16: USD 2024 Consolidated Income Statement (Unaudited)
USD 2024 Consolidated Income Statement (Unaudited) (USD million) Q1 2024* Q2 2024* Q3 2024* Q4 2024* Full Year 2024* Revenue 603 779 816 923 3,121 Cost of product sales (27) (28) (40) (48) (143) Research and Development expenses (335) (361) (336) (382) (1,414) Selling, general and administrative exp
Slide 17: USD 2024 Consolidated Balance Sheet (Unaudited)
(USD million) January 1, 2024* (USD million) January 1, 2024* USD 2024 Consolidated Intangible assets 15 Share capital Share premium 10 1,942 Balance Sheet (Unaudited) equipment Property and 142 Other reserves (2) Right-of-use assets 102 Retained earnings 2,736 Receivables 9 Shareholders’ equity 4,6
Slide 18: Rooted in Science, Inspired by Patients
Rooted in Science, Inspired by Patients © Genmab 2026. All rights reserved. These materials may not be distributed or reproduced, in whole or in part, without permission from Genmab. genmab.com
Genmab — 44th Annual J.P. Morgan Healthcare Conference 2026 on 6ix